News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Depomed, Inc. Completes Enrollment of Phase 3 Clinical Program of DM-1796 in Post-Herpetic Neuralgia
June 2, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has completed enrollment of the Phase 3 clinical trial of DM-1796 for the treatment of post-herpetic neuralgia.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
MORE ON THIS TOPIC
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
IN PARTNERSHIP WITH CURIUM
How radioligand therapy is rewriting cancer care
September 24, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Immunology and inflammation
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
September 23, 2026
·
2 min read
·
Annalee Armstrong
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
September 23, 2026
·
2 min read
·
Tristan Manalac
